Hangzhou Tigermed Consulting Co., Ltd. (HNGZY)
USD 4.0
(0.0%)
USD 4.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 2.91 Billion USD | -6.74% |
| 2022 | 2.93 Billion USD | 26.78% |
| 2021 | 3.89 Billion USD | 61.58% |
| 2020 | 2.41 Billion USD | 23.38% |
| 2019 | 1.17 Billion USD | -83.78% |
| 2018 | 683.63 Million CNY | 46.03% |
| 2017 | 473.45 Million CNY | 81.96% |
| 2016 | 256.65 Million CNY | 3.28% |
| 2015 | 255.6 Million CNY | 35.44% |
| 2014 | 188.15 Million CNY | 98.16% |
| 2013 | 96.29 Million CNY | 32.74% |
| 2012 | 74.77 Million CNY | 25.22% |
| 2011 | 58.17 Million CNY | 59.89% |
| 2010 | 36.87 Million CNY | 363.58% |
| 2009 | 7.79 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 336.51 Million CNY | -11.36% |
| 2024 Q1 | 352.86 Million CNY | -8.29% |
| 2024 Q2 | 455.37 Million CNY | 7.59% |
| 2023 Q2 | 874.19 Million CNY | 214.69% |
| 2023 FY | - USD | -6.74% |
| 2023 Q1 | 277.79 Million USD | 332.32% |
| 2023 Q4 | 1.57 Billion CNY | 490.13% |
| 2023 Q3 | -403.94 Million CNY | -146.21% |
| 2022 Q3 | 82.42 Million USD | -89.49% |
| 2022 Q4 | 64.25 Million USD | -22.04% |
| 2022 Q2 | 784.45 Million CNY | 57.66% |
| 2022 Q1 | 497.56 Million CNY | 4.94% |
| 2022 FY | - USD | 26.78% |
| 2021 Q2 | 58.01 Million CNY | 41.75% |
| 2021 FY | - USD | 61.58% |
| 2021 Q3 | 417.78 Million CNY | 620.11% |
| 2021 Q4 | 474.14 Million CNY | 13.49% |
| 2021 Q1 | 40.92 Million CNY | -91.29% |
| 2020 Q2 | 427.11 Million CNY | 305.32% |
| 2020 Q3 | 119.86 Million CNY | -71.94% |
| 2020 Q4 | 470.05 Million CNY | 292.17% |
| 2020 FY | - USD | 23.38% |
| 2020 Q1 | 105.37 Million CNY | -59.65% |
| 2019 Q3 | 239.96 Million CNY | -13.45% |
| 2019 Q4 | 261.16 Million CNY | 8.84% |
| 2019 FY | - USD | -83.78% |
| 2019 Q1 | 145.2 Million CNY | -41.6% |
| 2019 Q2 | 277.25 Million CNY | 90.94% |
| 2018 Q1 | 120.2 Million CNY | -35.17% |
| 2018 FY | - CNY | 46.03% |
| 2018 Q3 | 132.76 Million CNY | -28.43% |
| 2018 Q4 | 248.62 Million CNY | 87.27% |
| 2018 Q2 | 185.5 Million CNY | 54.33% |
| 2017 Q3 | 124.44 Million CNY | 4.72% |
| 2017 FY | - CNY | 81.96% |
| 2017 Q4 | 185.4 Million CNY | 48.99% |
| 2017 Q2 | 118.83 Million CNY | 58.93% |
| 2017 Q1 | 74.77 Million CNY | -7.28% |
| 2016 Q1 | 54.39 Million CNY | -34.41% |
| 2016 Q2 | 68.36 Million CNY | 25.68% |
| 2016 FY | - CNY | 3.28% |
| 2016 Q4 | 80.63 Million CNY | 82.04% |
| 2016 Q3 | 44.29 Million CNY | -35.2% |
| 2015 Q2 | 66.54 Million CNY | 49.36% |
| 2015 Q3 | 52.81 Million CNY | -20.63% |
| 2015 Q4 | 82.93 Million CNY | 57.04% |
| 2015 Q1 | 44.55 Million CNY | -35.59% |
| 2015 FY | - CNY | 35.44% |
| 2014 Q2 | 42.09 Million CNY | 23.45% |
| 2014 Q1 | 34.1 Million CNY | 40.2% |
| 2014 FY | - CNY | 98.16% |
| 2014 Q4 | 69.17 Million CNY | 54.15% |
| 2014 Q3 | 44.87 Million CNY | 6.6% |
| 2013 FY | - CNY | 32.74% |
| 2013 Q1 | 22.48 Million CNY | 15.66% |
| 2013 Q3 | 20.38 Million CNY | -26.35% |
| 2013 Q4 | 24.32 Million CNY | 19.29% |
| 2013 Q2 | 27.68 Million CNY | 23.11% |
| 2012 Q1 | 15.98 Million CNY | 13.09% |
| 2012 Q3 | 16.64 Million CNY | -13.02% |
| 2012 Q4 | 19.44 Million CNY | 16.83% |
| 2012 FY | - CNY | 25.22% |
| 2012 Q2 | 19.13 Million CNY | 19.7% |
| 2011 Q3 | 13.47 Million CNY | 0.0% |
| 2011 Q4 | 14.13 Million CNY | 4.9% |
| 2011 FY | - CNY | 59.89% |
| 2010 FY | - CNY | 363.58% |
| 2009 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 250668.863% |
| Arrayit Corporation | -3.07 Million USD | 94791.165% |
| Atlantic International Corp. | -5.38 Million USD | 54169.643% |
| Biocept, Inc. | -30.24 Million USD | 9736.308% |
| Bioqual, Inc. | 3.03 Million USD | -96004.394% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 384865.258% |
| DermTech, Inc. | -97.89 Million USD | 3076.838% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 14496.057% |
| iMD Companies, Inc. | -154.65 Thousand USD | 1884320.042% |
| IDenta Corp. | 71.58 Thousand USD | -4070633.338% |
| Interpace Biosciences, Inc. | 3.83 Million USD | -75847.768% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -7531861.424% |
| InVitro International | 6680.00 USD | -43624389.147% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 53707.724% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | 24016218.963% |
| Medical Imaging Corp. | -896.74 Thousand USD | 325067.033% |
| NovelStem International Corp. | -3.78 Million USD | 77074.923% |
| Optigenex Inc. | -1.18 Million USD | 245659.698% |
| PharmChem, Inc. | 1.05 Million USD | -276431.431% |
| Proteome Sciences plc | -1.13 Million USD | 256398.67% |
| Response Genetics, Inc | -19.66 Million USD | 14918.041% |
| Rennova Health, Inc. | -234.81 Thousand USD | 1241126.287% |
| RushNet, Inc. | -614.85 Thousand USD | 474054.037% |
| ScreenPro Security Inc. | -3.43 Million USD | 84938.72% |
| Stella Diagnostics Inc. | -5.7 Million USD | 51158.285% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 28474.646% |
| Todos Medical Ltd. | -9.39 Million USD | 31121.033% |